PRESENTATION
SMC Laboratories is highly regarded worldwide as a consulting CRO that designs studies in line with the demands of pharmaceutical companies and research institutions.
In particular, in the NASH-HCC field, SMC is a highly regarded CRO, because of our unique STAM™ mice.
The results achieved with our STAM™ have been introduced in academic publications as well as scientific conferences.
Presentations
2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 3000
No.37
HEP DART 2015,
“The Cyclophilin Inhibitor, CPI-431-32, is a Hepatitis B Oral Drug Candidate with Antiviral and Antifibrotic Activities” Ciclofilin Pharmaceuticals Inc.
No.36
WDC 2015,
“Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes” Dokkyo Medical University
No.35
AASLD 2015,
“Anti-Fibrotic Effect of Autotaxin and LPA1R Antagonists in a Rodent Model of NASH” Bristol-Myers Squibb Company
No.34
AASLD 2015,
“Sitagliptin, a Dipeptidyl Peptidase 4 inhibitor, Suppressed Tumor Progression with Down-regulation of Nrf Nuclear Expression in a Mouse Model of Non-alcoholic Steatohepatitis-related Hepatocellular Carcinoma” Kurume University School of Medicine
No.33
AASLD 2015,
“Reduction of Hepatic 27-Hydroxycholesterol in Steatohepatitis Model Mice with Insulin Resistance” Tokyo Medical University Ibaraki Medical Center
No.32
AASLD 2015,
“Disturbance of regulatory T cells, MDSCs and NK cells is involved in NASH and mouse model of NASH” Tohoku University Hospital.
No.31
AASLD 2015,
“Mechanism of Action of the Anti-NASH effects of Solithromycin in a Predictive NASH HCC Mouse Model” Cempra Pharmaceuticals, Inc.
No.30
DDW 2015,
“Effects of Sitagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Tumor Progression and p62/SQSTM1 Subcellular Localization in a Mouse Model of Non-Alcoholic Steatohepatitis-Related Hepatocellular Carcinoma” Kurume University
No.29
Keystone Symposia 2015,
DGAT2 Inhibition Prevents NAFLD and Fibrosis in the STAM™ Mouse Model of NASH“ Pfizer Inc.
No.28
Keystone Symposia 2015,
“Oxidized-Phospholipid Small Molecule Inhibits Non-Alcoholic Steatohepatitis (NASH) and Liver Fibrosis“ Vascular Biogenics Ltd